“Seeing patients is gratifying, but it’s on a different scale,” said Tweed-Kent, who earned a bachelor’s degree in chemical engineering from the University of Notre Dame. “As an entrepreneur, I’m potentially helping millions of patients.” – Ailis Tweed-Kent Thank you to Jon Saltzman for a great piece on physician entrepreneurs. It is a joy and […]
About Ailis Tweed-Kent
This author has yet to write their bio.Meanwhile lets just say that we are proud Ailis Tweed-Kent contributed a whooping 11 entries.
Entries by Ailis Tweed-Kent
BOSTON, Ma, February 16, 2017 – Cocoon Biotech, Inc., a biotechnology company focused on the development of osteoarthritis and other drug-delivery therapies based on its silk protein technology, has announced that Cocoon Founder and CEO, Ailis Tweed-Kent, M.D., has been named by the Boston Business Journal as one of the “2017 Women to Watch in […]
Cambridge, MA February 2, 2017 – Cocoon Biotech, Inc. (“Cocoon” or the “Company”), is a biotechnology company focused on utilizing its silk protein-based drug delivery technology for the development of formulations to treat osteoarthritis and other conditions for which many patients find existing treatments to be unsatisfactory. Cocoon announced today that it has entered into service […]
A panel of biotech VC and investment experts named Cocoon Biotech the Most Investable Company in a competition of 20 startups at the life science partnering event, held in mid-September in Boston. To learn more, visit the EBD Group Announcement. Also, visit the Cocoon Biotech, Inc. announcement on BioSpace.
Ailis Tweed-Kent, CEO and Founder of Cocoon Biotech, Inc., has been invited to speak at Bio-Europe Spring 2016, held April 4-6 in Stockholm, Sweden. On Monday, April 4 at 4:00 p.m. she will be a panelist on “The New Normal: Effective Alternative Financing,” and on Tuesday, April 5 at 11:30 p.m. she will tell the […]
BOSTON, Ma. — Cocoon Biotech, Inc. a biotechnology company focused on the development of osteoarthritis and other drug-delivery therapies based on its silk protein technology, has announced the appointment of Peter Mitchell, Ph.D., as Chief Scientific Officer. Dr. Mitchell brings to the position 25 years of commercial pharmaceutical leadership focused on arthritis and inflammation. To read […]
Dr. Ailis Tweed-Kent knew firsthand how badly those with the painful degenerative joint condition needed new treatments, and when she heard about Tufts University professor David Kaplan, who had just filed a patent for using silk for arthritis treatments, she jumped at the chance to meet him. To read more from The Boston Business Journal, visit this page.
In 2013, Dr. Ailis Tweed-Kent founded Cocoon Biotech Inc. to come up with a way to treat the actual cause of arthritis, the loss of cartilage in joints. For the therapy, she turned to a biomaterial that has been used for thousands of years: silk. To read more from STAT, visit this page.
Tufts Tech Transfer of Tufts University, one of Cocoon Biotech’s sponsoring research partners, recently named Cocoon as a featured startup, releasing a new article on Cocoon’s technology and mission. For more information and the full feature and interview visit their website.
Cocoon Biotech to Explore New Treatments for Joint Disease using Silk Biomaterial Platform Developed at Tufts University BOSTON (November 4th, 2014) — Cocoon Biotech today announced that it has entered into exclusive option and sponsored research agreements with Tufts University to explore the commercialization of new treatments for joint disease and arthritis using silk protein […]